Robert I. Blum, President and CEO of Cytokinetics Inc. (CYTK), executed a significant sale of company shares on September 15, 2026. Mr. Blum sold 97,926 shares at an average price of $69.33 per share, resulting in a transaction valued at approximately $6.79 million.
This transaction adds to recent insider selling activity at Cytokinetics. On the same day, Robert E. Landry also sold 1,000 shares. Earlier in the week, Mr. Blum sold an additional 7,500 shares, and Mr. Landry made another sale of 1,000 shares. Fady Ibraham Malik also reported a sale of 3,500 shares in the preceding week.
Insider sales can be driven by various factors including portfolio diversification, tax obligations, or pre-arranged trading plans and do not necessarily reflect a negative outlook on the company's future performance.